Condition
Onswik (insulin efsitora alfa-gobe) — once-weekly basal insulin for adults with type 2 diabetes
Onswik (insulin efsitora alfa) is a once-weekly long-acting insulin for adults with type 2 diabetes.
This is for adults with type 2 diabetes — and caregivers helping them — who may be candidates for a once-weekly basal insulin instead of a daily basal shot.
Mounjaro (tirzepatide) — weekly shot for adults with type 2 diabetes that now also carries a labelled heart-protection use
FDA supplemental approval effective 27 August 2026 for a new use of Mounjaro (tirzepatide) injection — a once-weekly subcutaneous dual GIP/GLP-1 receptor…
This is for adults with type 2 diabetes who are at high risk for heart attack, stroke, or cardiovascular death, and who may already be candidates for weekly…
Awiqli (insulin icodec / insulin icodec-abae) — once-weekly basal insulin
The first labelled once-weekly basal insulin.
Awiqli (insulin icodec) is a once-weekly long-acting insulin. The United States approved it in March 2026 only for adults with type 2 diabetes.